FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to pharmaceutics and dermatology, namely: to a topical composition for preventing, relieving symptoms or treating skin diseases or disorders containing from 0.015 to 0.035 wt. % of clobetasol in a solution of monoethyl ether of diethylene glycol, which serves as an intensifier of penetration, an aqueous phase and an oil phase; as well as to a method for preventing, reducing the intensity of symptoms or treating a painful skin condition involving the use of an effective amount of said composition on an individual.
EFFECT: group of inventions provides reducing side effects by reducing the amount of active substance while maintaining therapeutic effectiveness by improving its penetration through skin.
15 cl, 8 dwg, 11 ex, 16 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS INCLUDING COMBINATION OF CALCITRIOL AND CLOBESATOL PROPIONATE | 2003 |
|
RU2361594C2 |
| RETINOID COMPOSITIONS FOR TOPICAL APPLICATION | 2016 |
|
RU2699027C2 |
| APPLICATION OF COLOBETASOL-CONTAINING COMPOSITION FOR DISPERSION FOR TREATMENT OF PSORIASIS | 2006 |
|
RU2397769C2 |
| AEROSOL COMPOSITION CONTAINING COMBINATION OF CLOBETASOL PROPIONATE AND CALCITRIOL, ALCOHOLIC PHASE AND OIL PHASE | 2005 |
|
RU2384337C2 |
| METHODS FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS | 2017 |
|
RU2766577C2 |
| PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | 2013 |
|
RU2663117C2 |
| PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS FOR THEIR PRODUCTION AND USE | 2013 |
|
RU2789479C2 |
| COMBINATIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2002 |
|
RU2300379C2 |
| USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | 2014 |
|
RU2666219C2 |
| STABILISED COMPOSITION FOR TREATING PSORIASIS | 2009 |
|
RU2526162C2 |
